Get started
Author

Gokhan Tut

Observed name: Tut, Gokhan
ORCID: 0000-0002-0655-232X
Observed ORCID: 0000-0002-0655-232X
OpenAlex ID: A5029635737
Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection
2021 · Alexander C. Dowell, Megan S. Butler, et al. · Nature Immunology · 195
PDF
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study
2021 · Madhumita Shrotri, Maria Krutikov, et al. · The Lancet Infectious Diseases · 185
PDF
Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England
2021 · Maria Krutikov, Tom Palmer, et al. · The Lancet Healthy Longevity · 118
PDF
Measuring microtubule dynamics
2018 · Alexander James Zwetsloot, Gokhan Tut, et al. · Essays in Biochemistry · 87
PDF
Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study
2021 · Maria Krutikov, Tom Palmer, et al. · The Lancet Healthy Longevity · 65
Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study
2021 · Gokhan Tut, Tara Lancaster, et al. · The Lancet Healthy Longevity · 49
PDF
Outcomes of SARS-CoV-2 omicron infection in residents of long-term care facilities in England (VIVALDI): a prospective, cohort study.
2022 · Krutikov, Maria, Stirrup, Oliver, et al. · Northumbria Research Link (Northumbria University) · 45
Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5–6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis
2021 · Helen Parry, Rachel Bruton, et al. · The Lancet Healthy Longevity · 41
PDF
mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant
2021 · Helen Parry, Gokhan Tut, et al. · eLife · 36
Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study
2022 · Madhumita Shrotri, Maria Krutikov, et al. · The Lancet Healthy Longevity · 35
PDF
Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort study
2022 · Gokhan Tut, Tara Lancaster, et al. · The Lancet Healthy Longevity · 25
Strong peak immunogenicity but rapid antibody waning following third vaccine dose in older residents of care homes
2023 · Gokhan Tut, Tara Lancaster, et al. · Nature Aging · 24
PDF
COVID-19 vaccines elicit robust cellular immunity and clinical protection in chronic lymphocytic leukemia
2022 · Helen Parry, Rachel Bruton, et al. · Cancer Cell · 24
PDF
Single Vaccination with BNT162b2 or ChAdOx1 in Older People Induces Equivalent Antibody Generation but Enhanced Cellular Responses after ChAdOx1
2021 · Helen Marie Parry, Rachel Bruton, et al. · SSRN Electronic Journal · 17
BNT162b2 Vaccination in People Over 80 Years of Age Induces Strong Humoral Immune Responses with Cross Neutralisation of P.1 Brazilian Variant
2021 · Helen Marie Parry, Gokhan Tut, et al. · SSRN Electronic Journal · 17
Vaccine Effectiveness of the First Dose of ChAdox1 nCOV-19 and BNT162b2 Against SARS-CoV-2 Infection in Residents of Long Term Care Facilities (VIVALDI Study)
2021 · Madhumita Shrotri, Maria Krutikov, et al. · SSRN Electronic Journal · 16
Effectiveness of successive booster vaccine doses against SARS-CoV-2 related mortality in residents of long-term care facilities in the VIVALDI study
2023 · Oliver Stirrup, Madhumita Shrotri, et al. · Age and Ageing · 14
PDF
BNT162b2 vaccination in people over 80 years of age induces strong humoral immune responses with cross neutralisation of P.1 Brazilian variant
2021 · Parry, Helen, Tut, Gokhan, et al. · Zenodo (CERN European Organization for Nuclear Research) · 12
Clinical Effectiveness of SARS-CoV-2 Booster Vaccine Against Omicron Infection in Residents and Staff of Long-term Care Facilities: A Prospective Cohort Study (VIVALDI)
2022 · Oliver Stirrup, Madhumita Shrotri, et al. · Open Forum Infectious Diseases · 10
PDF
Changes in COVID-19 outbreak severity and duration in long-term care facilities following vaccine introduction, England, November 2020 to June 2021
2021 · Rebecca Giddings, Maria Krutikov, et al. · Eurosurveillance · 10
Anti-nucleocapsid antibody levels following initial and repeat SARS-CoV-2 infections in a cohort of long-term care facility residents in England (VIVALDI)
2024 · Oliver Stirrup, Gokhan Tut, et al. · Wellcome Open Research · 8
Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infection
2022 · Gokhan Tut, Tara Lancaster, et al. · Nature Aging · 8
PDF
Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI)
2022 · Oliver Stirrup, Maria Krutikov, et al. · The Journal of Infectious Diseases · 8
PDF
Nasal mucosal IgA levels against SARS-CoV-2 and seasonal coronaviruses are low in children but boosted by reinfection
2023 · Alexander C. Dowell, Gokhan Tut, et al. · Journal of Infection · 7
PDF
VIVALDI Cohort Profile: Using linked, routinely collected data and longitudinal blood sampling to characterise COVID-19 infections, vaccinations, and related outcomes in care home staff and residents in England
2023 · Maria Krutikov, David Bone, et al. · Wellcome Open Research · 4
Works count: 37
Citation count: 1,070
H-index: 16
I10-index: 20
Year
Topic
Type